Tag: CNS

Quality

Operational Challenges of Neuroscience Clinical Trials, Part 4: Assessment Subjectivity

In this blog series, we’ve been discussing some of the challenges of conducting clinical trials in neuroscience. In our final post of the series, we turn to another major one: ensuring that assessments are conducted with high quality whilst also minimizing subjectivity. Rating subjectivity can make signal detection substantially more difficult, if not impossible. This...

Clinical Research: Phase 1 - Phase 4

Operational Challenges of Neuroscience Clinical Trials, Part 1: Overview

With billions of neurons, the brain is the most complex organ in the body, so it’s not surprising that neuroscience clinical trials—more so than trials in other medical specialties—face major challenges, both conceptual and practical. In this new blog series, we’ll look at the challenges sponsors face when operationalizing clinical trials and share lessons from...

Clinical Research: Phase 1 - Phase 4

A Vast Unmet Need: Challenges In Alzheimer’s Clinical Trials

Dementia is a growing global epidemic, affecting nearly 47 million people worldwide. That number is expected to approach 75 million by 2030, when the cost of patient care is forecast to reach $2 trillion. And the trend will only accelerate: By 2050, it’s estimated that 115 million will suffer from some form of dementia. Alzheimer’s...

Patient and Stakeholder Engagement

7 Ways to Engage Military Vets in PTSD Clinical Trials

Combat related trauma is significantly affecting U.S. military veterans compared to other military populations across the globe. As many as 20 percent of the U.S. military veterans who served in Iraq and Afghanistan and up to 30 percent of those who fought in the Vietnam War will suffer from Post-Traumatic Stress Disorder (PTSD) in a...

Consulting

Success in Neurodegenerative Disease Trials: Attend Our Nov. 15 Webinar

DURHAM, N.C., November 10, 2016 — Researchers developing treatments for neurodegenerative disorders face some of the biggest hurdles in planning and conducting clinical drug trials. Get advice on navigating this difficult terrain by attending a Premier Research webinar on Tuesday, November 15. Neurodegenerative Disease Research: Steps to a Successful Clinical Trial will describe a complex...

Premier Research Strategist to Discuss Evolving Site Landscape at CNS Summit

DURHAM, N.C., October 26, 2016 — Premier Research’s lead strategist will participate in a panel discussion on the evolving landscape for investigator sites at CNS Summit 2016 in Boca Raton, Florida. Krista Armstrong, Vice President of Strategic Development, will join colleagues in addressing topics such as: Advantages and disadvantages of site consolidation Site selection and strategic...

Premier Research Expands Staffing Amid Growing Demand for Neuroscience Studies

DURHAM, N.C., May 23, 2016 — As demand for neuroscience clinical trials grows, Premier Research has named neuroscience expert Dr. Susan Kozauer Senior Medical Director for Psychiatry. Kozauer joins recent hires Anne Marie Nagy, Ph.D., Dr. Teresa Nunes, Dr. Carol Gaines, and Todd Leathers on a team that has performed almost 400 neurology and psychiatry...

Medical Director Authors Novel Look at Kleefstra Syndrome

DURHAM, N.C., April 1, 2016 — A paper authored by a Premier Research medical director takes an unprecedented look at motor function and behavior in adults and children with Kleefstra syndrome. Susanne Schmidt, M.D., Ph.D., and four Norwegian colleagues published their findings in the European Journal of Medical Genetics. The study of four male and...

Premier Research Names Todd Leathers Executive Director for CNS

PHILADELPHIA, December 15, 2015 — Premier Research announces the appointment of Todd Leathers as Executive Director focusing on central nervous system studies. In this new role, Leathers will be responsible for strategic development and oversight of operational, regulatory, medical, and scientific planning for study design and implementation. He comes to Premier Research from Acurian, a...